The progress and perspective of strategies to improve tumor penetration of nanomedicines

Hu, Jiang; Yuan, Xinwei; Wang, Fei; Gao, Huile; Li, Xilin; Zhang, Wei

doi:10.1016/j.cclet.2020.11.006

Cited by 126 publications

(59 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 139 ] Particle size is an important parameter to determine the penetration ability of a nanomedicine, and small‐sized nanoparticles are more likely to pass through the dense TEM. [ 15 , 140 ] In recent years, enzyme‐responsive nanomedicine has offered a solution to solve this problem. [ 141 ] To improve the tumor penetration of nanomedicine into tumors, Ma and co‐workers developed an enzyme‐responsive prodrug that was composed of a PEGylated IDO inhibitor conjugated by the peptide sequence PVGLIG and indocyanine green (ICG) ( Figure 7 a ).…”

Section: Tme‐responsive Nanomedicine For Immunotherapymentioning

confidence: 99%

“…[ 14 ] Nanomedicines exhibit the advantage of preferentially accumulating in solid tumors due to the abnormally leaky vasculature and dysfunctional lymphatic drainage within the TME, which are well‐known as the enhanced permeability and retention (EPR) effect. [ 15 ] Numerous studies have shown that nanomedicines exhibit the advantages of controllable drug delivery and modular flexibility, which provide an opportunity for immunotherapy to promote clinical transformation in a safe and effective manner. [ 16 ] For example, a nanomedicine‐based drug delivery system could reduce off‐target toxicity and immune‐related adverse events, which are particularly significant for potent immunotherapies that could cause severe dose‐limiting toxicity, such as the cytokine storm.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Tumor‐Microenvironment‐Responsive Nanomedicine for Enhanced Cancer Immunotherapy

et al. 2021

Self Cite

View full text Add to dashboard Cite

The past decades have witnessed great progress in cancer immunotherapy, which has profoundly revolutionized oncology, whereas low patient response rates and potential immune-related adverse events remain major clinical challenges. With the advantages of controlled delivery and modular flexibility, cancer nanomedicine has offered opportunities to strengthen antitumor immune responses and to sensitize tumor to immunotherapy. Furthermore, tumor-microenvironment (TME)-responsive nanomedicine has been demonstrated to achieve specific and localized amplification of the immune response in tumor tissue in a safe and effective manner, increasing patient response rates to immunotherapy and reducing the immune-related side effects simultaneously. Here, the recent progress of TME-responsive nanomedicine for cancer immunotherapy is summarized, which responds to the signals in the TME, such as weak acidity, reductive environment, high-level reactive oxygen species, hypoxia, overexpressed enzymes, and high-level adenosine triphosphate. Moreover, the potential to combine nanomedicine-based therapy and immunotherapeutic strategies to overcome each step of the cancer-immunity cycle and to enhance antitumor effects is discussed. Finally, existing challenges and further perspectives in this rising field with the hope for improved development of clinical applications are discussed.

show abstract

Section: Tme‐responsive Nanomedicine For Immunotherapymentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Tumor‐Microenvironment‐Responsive Nanomedicine for Enhanced Cancer Immunotherapy

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Some studies have been devoted to the preparation of targeted DDS to provide selective and sensitive transportation of highly cytotoxic anti-cancer. Tumor penetration is important for effectively tumor targeting DDS (Hu et al., 2021 ). These DDS could improve pharmacokinetic and increase therapeutic efficiency of anti-cancer agents while decreasing normal tissue toxicity (Oroojalian et al., 2018 ; Ren et al., 2021 ).…”

Section: Introductionmentioning

confidence: 99%

Co-delivery of paclitaxel (PTX) and docosahexaenoic acid (DHA) by targeting lipid nanoemulsions for cancer therapy

Tan

Chu

et al. 2021

Drug Delivery

View full text Add to dashboard Cite

Breast cancer is one of the most common types of cancer in female patients with high morbidity and mortality. Multi-drug chemotherapy has significant advantages in the treatment of malignant tumors, especially in reducing drug toxicity, increasing drug sensitivity and reducing drug resistance. The objective of this research is to fabricate lipid nanoemulsions (LNs) for the co-delivery of PTX and docosahexaenoic acid (DHA) with folic acid (FA) decorating (PTX/DHA-FA-LNs), and investigate the anti-tumor activity of the PTX/DHA-FA-LNs against breast cancer both in vitro and in vivo . PTX/DHA-FA-LNs showed a steady release of PTX and DHA from the drug delivery system (DDS) without any burst effect. Furthermore, the PTX/DHA-FA-LNs exhibited a dose-dependent cytotoxicity and a higher rate of apoptosis as compared with the other groups in MCF-7 cells. The cellular uptake study revealed that this LNs were more readily uptaken by MCF-7 cells and M2 macrophages in vitro . Additionally, the targeted effect of PTX/DHA-FA-LNs was aided by FA receptor-mediated endocytosis, and its cytotoxicity was proportional to the cellular uptake efficiency. The anti-tumor efficiency results showed that PTX/DHA-FA-LNs significant inhibited tumor volume growth, prolonged survival time, and reduced toxicity when compared with the other groups. These results indicated that DHA increases the sensitivity of tumor cells and tumor-associated macrophages (ATM2) to PTX, and synergistic effects of folate modification in breast cancer treatment, thus PTX/DHA-FA-LNs may be a promising nanocarrier for breast cancer treatment.

show abstract

“…The abnormal biology of the tumor microenvironment (TME) –including the abnormal vasculature, the elevated interstitial fluid pressure (IFP), and the dense extracellular matrix (ECM)– prevent the efficient delivery of nanoparticles [ 20 , 21 ]. Many approaches have been developed to target the TME to overcome these barriers and enhance penetration depth [ 22 , 23 ], including normalization of the vasculature [ 24 , 25 ], alleviation of mechanical stress [ 26 ], reduction of tumor hypoxia [ 27 , 28 ], reprogramming tumor-associated fibroblasts (TAFs) [ 29 , 30 ], and modulating tumor-associated macrophage (TAM) phenotype [ 31 , 32 ]. The success of such approaches depends on the type of tumor and the specific properties of the nanoparticles, so these methods are not effective in every clinical situation.…”

Section: Introductionmentioning

confidence: 99%

Towards principled design of cancer nanomedicine to accelerate clinical translation

Souri

Soltani

Kashkooli

et al. 2022

Materials Today Bio

View full text Add to dashboard Cite

The progress and perspective of strategies to improve tumor penetration of nanomedicines

Cited by 126 publications

References 67 publications

Tumor‐Microenvironment‐Responsive Nanomedicine for Enhanced Cancer Immunotherapy

Tumor‐Microenvironment‐Responsive Nanomedicine for Enhanced Cancer Immunotherapy

Co-delivery of paclitaxel (PTX) and docosahexaenoic acid (DHA) by targeting lipid nanoemulsions for cancer therapy

Towards principled design of cancer nanomedicine to accelerate clinical translation

Contact Info

Product

Resources

About